Image source: Getty Images.
There are roughly 56 million eligible Americans that count on Medicare (or Medicare Advantage plans) to help maintain their physical and financial well-being each and every month. Of these 56 million, about five in six are aged 65 and up. Without Medicare to step in and cover a lion’s share of their eligible medical costs during retirement, it’s possible the poverty rate for seniors would be considerably higher than it is now.
Original Medicare, which roughly 70% of eligible members are still enrolled in, is comprised of three key components: Part A, Part B, and Part D.
Part A, also known as hospital insurance, covers in-patient hospital stays, surgeries, and long-term skilled nursing care, as an example. The great thing about Part A is that there’s no premium required for a vast majority of Americans. Just as 40 lifetime work credits qualifies someone to receive Social Security benefits during retirement, 40 lifetime work credits also allows an individual to receive Medicare Part A without a premium once they reach age 65, or have other extenuating circumstances arise, such as becoming disabled.
- [By Matthew Briar]
What do you get when you cross a science that drastically improves the absorption of cannabidiol (the healthy component of cannabis) with pterostilbene (an antioxidant) tablet? It’s not a joke in search of a punch line. It’s going to be the health supplement millions of consumers have been waiting for, brought to them by a joint venture between NeutriSci International Inc (CVE:NU) and Lexaria Bioscience Corp (OTCMKTS:LXRP). The two companies announced this morning they were entering a joint venture that would utilize Lexaria Bioscience’s proprietary infusion platform and tap into NeutriSci International’s existing distribution network to create and market a whole new supplement product line.
Lexaria has developed and patented a technology that makes valuable molecules taste better and absorb better in the digestive tract. This platform could be applied to a variety of nutritional and health-oriented favorites, but Lexaria is starting with hemp as it’s the most underserved market and arguably the biggest growth opportunity.
Just to be clear, hemp and marijuana are not the same thing. Hemp doesn’t have any tetrahydrocannabinol (or THC) in it, which is the key driver of its psychoactive — the ‘high’ — response. Hemp, and hemp oil to be exact, does have cannabidiol in it though, and for those who’ve been following the saga of medical marijuana and cannabis, they’ll know cannabidiol can provide a lot of various medical benefits like the reduction of nausea, control of seizures, anti-cancer activity, anti-inflammation effects, and more.
NeutriSci International is Canadian corporation that specializes in the marketing, development and distribution of proprietary nutraceuticals. It’s got a rather wide array of products in its portfolio, but the one of immediate interest is its pterostilbene, as it fits best with the hemp-absorption technology Lexaria Bioscience brings to the table.
Pterostilbene (found in blueberries, by the way) is o
- [By James E. Brumley]
Are hemp and marijuana one and the same? It depends who you ask. The federal government accurately recognizes that hemp and marijuana are variants of the same species, Cannabis sativa. Yet, poodles and German shepherds are also from the same species, and the two couldn’t be any more different types of dogs. The same goes for marijuana and hemp. The difference between hemp and marijuana is primarily the amount of tetrahydrocannabinol (or THC), which is the primary psychoactive chemical in marijuana. Hemp contains less than 0.5% THC, while marijuana consists of anywhere from 6 % to 20% (and sometimes more) THC.
The good news is, governments – federal and state – are finally starting to wise up to the distinct differences between marijuana and hemp, and that bodes well for a young startup called Lexaria Bioscience Corp (OTCMKTS:LXRP).
Lexaria Bioscience Corp. is “a food biosciences company with a proprietary technology for improved delivery of bioactive compounds. The Company’s lipophilic enhancement technology has been shown to enhance the bioavailability of orally ingested cannabinoids, while also masking taste. This technology promotes healthy ingestion methods, lower overall dosing and higher effectiveness in active molecule delivery. The Company’s technology is patent-protected for cannabidiol (CBD) and all other non-psychoactive cannabinoids, and patent-pending for Tetrahydrocannabinol (THC), other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.”
In other words, it solves a problem within the budding (no pun intended) world of cannabis and medical — or even recreational — marijuana. It increases the amount of absorption of a substance ingested.
The science has applications in everything from vitamins to supplements to painkillers, but LXRP is starting with the hemp oil for good reason.
Hemp seeds (which are technically a nut and are als
- [By Bryan Murphy]
At first glance, it looks like it could be trouble for Lexaria Bioscience Corp (OTCMKTS:LXRP). That is, on Wednesday, the nation’s Drug Enforcement Agency brought clarity to a rule that had been up in the air since 2011. That is, in short, the DEA’s position on all cannabis extracts, including CBD oil, is that they are all federally illegal Schedule I substances.
From a legal and logical standpoint based just on the DEA’s language published in the Federal Register yesterday, that puts Lexaria Bioscience in jeopardy. Lexaria has developed a way to improve the body’s absorption of hemp oil — which is deliberately high in cannabidiol/CBD — which was perfectly legal and legitimate since THC percentage in hemp (0.3%or less) are technically legal. Now the federal government’s drug-enforcement arm says that’s not the case. The newly-clarified law defines the illegal substance as “extracts that have been derived from any plant of the genus Cannabis and which contain cannabinols and cannabidiols.” Hemp, even though it’s not marijuana, is of the Cannabis genus.
Bad news for LXRP owners? Not quite, for a handful of reasons.
The decision (which bypassed legislature and overstepped the DEA’s authority, by the way – more on that in a second) is evidence of a long-standing problem the government agency has had in dealing with hemp and cannabis. In simplest terms, the DEA has operated and acted as if it has no real understanding of the difference between hemp and marijuana. They are of the same genus, but not of the same species. Moreover, while the former predominantly contains cannabidiol, the latter is sought out for its high tetrahydrocannabinol (or THC) for the purpose of creating a “high.”
Problem (for the DEA): The U.S. judicial system has already ruled that the DEA doesn’t have the authority to make such rules.
Attorney Robert Hoban explained yesterday evening at industry website newcannabisventures.com:
- [By Matthew Briar]
Granted, it’s not always a fully-appreciated distinction. Even though the federal government accurately recognizes that hemp and marijuana are only variants of the same species, Cannabis sativa, the DEAdoesn’t necessarily enforce its drug laws as such. For legitimate medical purposes, the government is perfectly willing to leave the matter alone.
The good news is, governments – federal as well as state – are finally starting to figure out the distinct differences between marijuana and hemp, and that bodes well for a young and hungry startup called Lexaria Bioscience Corp (OTCMKTS:LXRP).
- [By Matthew Briar]
Last week — to the day, in fact — Lexaria Bioscience Corp (OTCMKTS:LXRP) announced it was teaming up with neutraceutical company NeutriSci International Inc (CVE:NU) to create a new kind of health supplement that gave consumers the ability to tap into the benefits of hemp. We hailed it as the shape of things to come. What we didn’t know, however, was how quickly those things would take shape. Just this morning the company told LXRP shareholders it was already forging another such symbiotic relationship…. this one with Hempco Food and Fiber Inc (CVE:HEMP).
Simply put, Lexaria Bioscience is focused on improving the bioavailability of the healthy stuff found in food, supplements, vitamins, and yes, even in cannabis and hemp.
It’s not widely recognized, but the bulk of the vitamins, anti-oxidants, minerals, amino acids and all the other desirable components of the pills you take and foods you eat don’t actually get absorbed into your body. Sometimes as much as 96% of the ingredient in question isn’t extracted, and instead passes right through. Not only is it a waste of time and money, it’s a bit of a hassle to swallow a big capsule — or several capsules — for little to no benefit.
Lexaria Bioscience changes this. In short, Lexaria has developed and patented a proprietary technology that makes valuable molecules taste better and absorb better in the digestive tract. This platform could be applied to a variety of nutritional and health-oriented favorites, but Lexaria is starting with hemp as it’s the most underserved market and arguably the biggest growth opportunity. Hemp, and hemp oil to be exact, can provide a lot of various medical benefits like the reduction of nausea, control of seizures, anti-cancer activity, anti-inflammation effects, and more.
The future for Lexaria Bioscience is partnerships… licensing its science and know-how to companies with existing product lines and distribution networks that can easily inject hemp
- [By Bryan Murphy]
In the grand scheme of things it shouldn’t be surprising, though odds are good at least a few people are surprised at how quickly it happened. That is, health supplement and healthy-foods brand name NeutriSci International Inc (CVE:NU) and the developer of a cannabis-infusion technology — a means of packing more CBD into hemp oil — called Lexaria Bioscience Corp (OTCMKTS:LXRP) have finalized new supplement that is done testing and will soon be available for consumers. The tablet (a ‘melt’, technically) is a combination of pterostilbene and cannabidiol, offering a double-barreled benefit to the health-conscious.
The benefits of cannabidiol, found in hemp and marijuana, are relatively well understood by the market at this point. Cannabidiol can do a human body a lot of good, like the reduction of nausea, control of seizures, anti-cancer activity, anti-inflammation effects, and more. Pterostilbene is the lesser-known of the two components of the new tablet, but no less impressive and no less beneficial. Pterostilbene is known to combat high cholesterol, high blood pressure, and oxidative stress. Combining the two is a real one-two punch for the health-conscious.
That’s what made November’s news so exciting… NeutriSci International has an established name and marketing channel, while Lexaria Bioscience has the science that makes hemp oil far more functional. Indeed, to fully appreciate the upside for LXRP, one has to embrace Lexaria’s science and why it matters.
The bulk of the vitamins, anti-oxidants, minerals, amino acids and all the other desirable components of the pills you take and foods you eat don’t actually get absorbed into your body. Sometimes as much as 96% of the ingredient in question isn’t extracted, and instead passes right through. Not only is it a waste of time and money, it’s a bit of a hassle to swallow a big capsule — or several capsules — for little to no benefit.
Lexaria Bioscience changes this. In short,